Background Congenital myasthenic syndromes (CMS) are rare inherited heterogeneous disorders of neuromuscular transmission. Aims and methodology This study aims to describe clinical and investigative characteristics including genetic aspects of patients with congenital myasthenic syndrome (CMS), in a cohort from western India. Retrospective analysis for the study period of 9 years (−January 2013 to December 2021) was performed. Patients were identified by predefined selection criteria using a combination of clinical, electrophysiological, and genetic studies. Results Fifteen genetically evaluated CMS patients, 11 females, and 4 males were identified. Ten patients had a history of fatigable ptosis at an early age, whereas all patients had varying degrees of proximal weakness at the time of presentation. The mean age at onset was 16 years and the mean age at final diagnosis was 22 years, thereby representing a mean delay in diagnosis of 6 years. Among the total 13 different genetic mutations identified, 4 are not previously reported. The most common genetic mutations identified were CHRNE gene (in 7 patients) followed by DOK7 gene (in 6 patients), and the remaining 2 patients had mutation in MUSK gene. Roma founder mutation (c.1327delG, p.E443ter) was seen in 5 patients with CHRNE gene. Four patients responded to pyridostigmine alone, 7 patients to salbutamol, whereas 4 patients required a combination of pyridostigmine and salbutamol. Conclusion This study, carried out in a small cohort of patients, highlights the frequent occurrence of Roma founder mutation in our population, and the predominance of CHRNE and DOK7 gene mutations, points of regional importance. Four novel variants were also identified in the genetic studies carried out.
Congenital myasthenic syndromes (CMS) are phenotypically heterogeneous disorders with defects at presynaptic, synaptic and postsynaptic level. With the worldwide prevalence of CMS unknown, from India either case reports or hospital based studies 1-3 give insight into the spectrum of CMS. At present more than 20 genes have been associated with CMS, majority are CHRNE (50%, including both autosomal dominant and recessive), RAPSN (15%-20%), DOK7 (10%-15%), COLQ (10%-15%), GFPT1 (2%).4 We are reporting 4 cases of CMS with typical presentation of fatiguable ptosis at early age in all patients and limb girdle weakness in two patients. One presented with history of respiratory arrest after fluoroquinolone use. All of them had positive slow rate repetitive nerve stimulation (RNS). Two patients had pathogenic compound heterozygous and homozygous mutations respectively for CHRNE, one patient had heterozygous mutation for SLC25A1 with uncertain significance with one patient’s report unknown. Two patients (one CHRNE and SLC25A1) responded with pyridostigmine only and two patients responded to pyridostigmine and salbutamol.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.